| Drug-target interactions: prediction methods and applications S Anusuya, M Kesherwani, KV Priya, A Vimala, G Shanmugam, ... Current Protein and Peptide Science 19 (6), 537-561, 2018 | 38 | 2018 |
| Amarogentin, a secoiridoid glycoside, activates AMP-activated protein kinase (AMPK) to exert beneficial vasculo-metabolic effects UR Potunuru, KV Priya, MKNS Varsha, N Mehta, S Chandel, N Manoj, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1863 (8), 1270-1282, 2019 | 27 | 2019 |
| Importance of functional groups in predicting the activity of small molecule inhibitors for Bcl‐2 and Bcl‐xL V Kanakaveti, R Sakthivel, SK Rayala, MM Gromiha Chemical biology & drug design 90 (2), 308-316, 2017 | 18 | 2017 |
| Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery V Kanakaveti, A Shanmugam, C Ramakrishnan, P Anoosha, R Sakthivel, ... Advances in protein chemistry and structural biology 121, 25-47, 2020 | 13 | 2020 |
| Protein Interactions: computational methods, analysis and applications MM Gromiha World Scientific, 2020 | 10 | 2020 |
| Ligand‐Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors NK Prasad, V Kanakaveti, S Eadlapalli, R Vadde, AP Meetei, V Vindal Journal of Chemistry 2013 (1), 679459, 2013 | 10 | 2013 |
| Forging new scaffolds from old: Combining Scaffold hopping and Hierarchical virtual screening for identifying novel Bcl-2 inhibitors V Kanakaveti, S Rathinasamy, SK Rayala, M Gromiha Current Topics in Medicinal Chemistry 19 (13), 1162-1172, 2019 | 6 | 2019 |
| Quantitative structure–activity relationship in ligand-based drug design: Concepts and applications V Kanakaveti, P Anoosha, R Sakthivel, SK Rayala, MM Gromiha Protein interactions: computational methods, analysis and applications, 333-349, 2020 | 5 | 2020 |
| Influence of amino acid mutations and small molecules on targeted inhibition of proteins involved in Cancer V Kanakaveti, P Anoosha, R Sakthivel, SK Rayala, MM Gromiha Current Topics in Medicinal Chemistry 19 (6), 457-466, 2019 | 4 | 2019 |
| Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer MMG Vishnupriya Kanakaveti,Sakthivel Ramasamy, Rahul Kanumuri, Vaishnavi ... Cancers 14 (21), 5241, 2022 | 3 | 2022 |
| Protein Interactions as Targets in Drug Discovery R Donev Academic Press, 2020 | 1 | 2020 |
| MYC Inactivation Restores Immune Surveillance in a Transgenic Mouse Model of T-Cell Acute Lymphoblastic Lymphoma DF Atibalentja, V Kanakaveti, LE Yao, DW Felsher Blood 144 (Supplement 1), 1612-1612, 2024 | | 2024 |
| Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma SP Fricker, CJ Nicholson, SJ Roth, A Singh, C Brown, J Hu, P Buiga, ... Blood Cancer Discovery 5 (3_Supplement), PO-037-PO-037, 2024 | | 2024 |
| Abstract LB005: Identification of novel targets for MYC-driven hepatocellular carcinoma via transomics SP Fricker, CJ Nicholson, SJ Roth, A Singh, C Brown, J Hu, P Buiga, ... Cancer Research 84 (7_Supplement), LB005-LB005, 2024 | | 2024 |
| Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer. V Kanakaveti, S Ramasamy, R Kanumuri, V Balasubramanian, ... Cancers 14 (21), 5241-5241, 2022 | | 2022 |
| Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery SK Rayala, C Ramakrishnan, A Shanmugam, V Kanakaveti, R Sakthivel, ... (No Title), 2020 | | 2020 |
| Drug-Target Interactions Classification T Shi, X Sun, QY He, S Anusuya, M Kesherwani, KV Priya, A Vimala Current Protein and Peptide Science 19 (6), 525, 2018 | | 2018 |
| Research Article Ligand-Based Pharmacophore Modeling and Virtual Screening of RAD9 Inhibitors NK Prasad, V Kanakaveti, S Eadlapalli, R Vadde, AP Meetei, V Vindal | | 2013 |
| Targeted inhibition of BCL 2 proteins A structural and molecular approach V Kanakaveti Chennai, 0 | | |
